BenchSci
PrivateLast Round
Series D
May 25, 2023
Total Funding Raised
$159.94M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BenchSci operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series D round in May 2023.
BenchSci is a biotechnology company that offers a research intelligence platform leveraging machine learning and artificial intelligence to optimize antibody extraction experiments, helping researchers accelerate biomedical discoveries efficiently.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BenchSci Comparables
Compare BenchSci with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insilico Medicine | 87% | |
| Causaly | 85% | |
| Biorelate | 78% |
For institutional investors. Book with your work email.
BenchSci Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 25, 2023 | ||||
| Series C | Jan 24, 2022 | ||||
| Series B | Feb 4, 2020 | ||||
| Series A Extension | Jun 25, 2019 | ||||
| Series A | May 2, 2018 | ||||
Seed | Jul 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BenchSci Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gradient Ventures | Series B, Series A, Series D, Series C, Series A Extension |
| Northleaf Capital Partners | Series B, Series C |
| Fidelity Investments Canada ULC | Series D, Series C, Series B |
| TCV | Series D, Series C |
| Inovia Capital | Series B, Series D, Series A Extension, Series A, Series C |
| F-Prime Capital | Series D, Series C, Series B |
| Creative Destruction Lab | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Achieved 247% growth over three years, recognized by Deloitte.
- Apr 21, 2026
Platform used by 9 of top 10 pharma companies across 4,500+ research centers.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 22, 2026
Deloitte names BenchSci to its 2025 Technology Fast 500.
- partners_withSep 2, 2026
On Sep 2nd '26 in Canada, BenchSci and Argenx announce a two-year enterprise agreement to deploy EMET, an agentic research environment for AI-driven preclinical drug discovery.
For institutional investors. Book with your work email.
BenchSci Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BenchSci's valuation, stock price, and market status.
Is BenchSci a public or private company?
BenchSci is a private company.
What is the current stock price of BenchSci?
BenchSci is a private company, so its shares have no public market price. Caplight tracks BenchSci's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BenchSci worth (valuation)?
Valuation information for BenchSci is not publicly available.
Can I buy BenchSci stock?
BenchSci shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BenchSci's last funding round?
BenchSci's most recent funding round was Series D on May 25, 2023.
Who are the main investors in BenchSci?
Key investors in BenchSci include Gradient Ventures, Fidelity Investments Canada ULC, TCV, Inovia Capital, F-Prime Capital.
Will BenchSci IPO soon?
No public IPO plans have been announced for BenchSci.
How can I track BenchSci secondary market activity?
Caplight tracks bids, offers, and trades in BenchSci's shares on secondary markets.